Alessandra Larocca
0000-0002-2070-3702
Publication & Citation Trends
Publications
235 total
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial OA
Cited by 4
Semantic Scholar
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial.
Cited by 0
Semantic Scholar
Bortezomib-melphalan-prednisone (VMP) +/- daratumumab (DVMP) vs. lenalidomide-dexamethasone (Rd) +/- daratumumab (DRd) in transplant-ineligible real-life multiple myeloma patients: Results from the randomized phase IV real MM trial
Cited by 0
Semantic Scholar
Bortezomib-melphalan-prednisone versus lenalidomidedexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial
Cited by 0
Semantic Scholar
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.
Cited by 1
Semantic Scholar
Fixed-duration teclistamab and talquetamab for frail patients with newly diagnosed multiple myeloma: The EMN37 fitfix study
Cited by 1
Semantic Scholar
Incidence and characteristics of myeloid neoplasms in patients with multiple myeloma treated with novel myeloma-directed therapies
Cited by 0
Semantic Scholar
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
Cited by 6
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(221)
Protein Degradation and Inhibitors
(115)
Cancer Treatment and Pharmacology
(73)
Peptidase Inhibition and Analysis
(66)
Histone Deacetylase Inhibitors Research
(18)
Affiliations
Novartis (Switzerland)
Amgen (United States)
Janssen (Belgium)
Bristol-Myers Squibb (Germany)
Cornell University